Nearly half of atrial fibrillation (AF) patients on vitamin K antagonist (VKA) with prior time in therapeutic range (TTR) ≥70 percent had TTR <70 percent during the following year, reports a recent study. Additionally, there is limited long-term prognostic value for prior TTR ≥70 percent.
Rheumatoid arthritis (RA) disease control appears to be better with continued 4-mg baricitinib treatment than with a 2-mg dose step-down approach, according to substudy data from the ongoing phase III RA-BEYOND extension trial.
In patients receiving foecal microbiota transplantation (FMT) for the treatment of Clostridium difficile infection (CDI), high levels of Candida albicans may be associated with poor outcomes, a recent study has shown.
A novel light therapy which combines infrared, red and violet light emitted through LEDs* appears safe and improves the conditions of finger ulcers in patients with systemic sclerosis (SSc), a pilot study shows.
The use of fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI compared with interferon beta-1a in paediatric patients with relapsing multiple sclerosis (MS), the phase III PARADIGMS study has shown.
Acute coronary syndrome (ACS) patients with prasugrel contraindications tend to have worse in-hospital and postdischarge prognosis, according to a recent study, which reports that ticagrelor may be an effective alternative.
Lifestyle interventions incorporating diet and exercise slash the need for antihypertensive medications by more than half among overweight or obese adults with high blood pressure (BP), according to a secondary analysis of the ENCORE trial presented at the Joint Hypertension 2018 Scientific Sessions.
A significant association exists between fluoroquinolone exposure and aortic aneurysm and dissection (AA/AD), suggests a recent study. Duration of fluoroquinolone use and length of the hazard period modify this risk.
Treatment with low-dose aspirin appears to reduce the risk of serious vascular events in diabetic individuals without evident cardiovascular disease at baseline, although this risk decrease is achieved with an accompanying increase in the rates of major bleeding events, according to data from the ASCEND trial.
Long-term treatment with memantine is well tolerated but does not effectively prevent glaucomatous progression in patients with open-angle glaucoma (OAG), according to the results of two phase III trials.
Results from a trio of papers detailing the Heart Outcomes Prevention Evaluation (HOPE)-3 trial demonstrated that cholesterol-lowering statin therapy plus two blood pressure drugs reduced the risk of cardiovascular events in intermediate risk patients with average cholesterol and blood pressure levels.